WO2002049645A1 - Therapeutic combination of amlodipine and benazepril - Google Patents

Therapeutic combination of amlodipine and benazepril Download PDF

Info

Publication number
WO2002049645A1
WO2002049645A1 PCT/US2000/034246 US0034246W WO0249645A1 WO 2002049645 A1 WO2002049645 A1 WO 2002049645A1 US 0034246 W US0034246 W US 0034246W WO 0249645 A1 WO0249645 A1 WO 0249645A1
Authority
WO
WIPO (PCT)
Prior art keywords
benazepril
amiodipine
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Application number
PCT/US2000/034246
Other languages
French (fr)
Inventor
William Lionel Daley
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21742073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002049645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to NZ526385A priority Critical patent/NZ526385A/en
Priority to JP2002550985A priority patent/JP2004516266A/en
Priority to CZ20031678A priority patent/CZ20031678A3/en
Priority to HU0302455A priority patent/HUP0302455A3/en
Priority to PL00362252A priority patent/PL362252A1/en
Priority to MXPA03005462A priority patent/MXPA03005462A/en
Priority to PCT/US2000/034246 priority patent/WO2002049645A1/en
Priority to BR0017386-0A priority patent/BR0017386A/en
Priority to AU2001225816A priority patent/AU2001225816B2/en
Priority to EP00989288A priority patent/EP1365761A1/en
Priority to CN00820080A priority patent/CN1461218A/en
Priority to CA002432638A priority patent/CA2432638A1/en
Priority to IL15613600A priority patent/IL156136A0/en
Priority to AU2581601A priority patent/AU2581601A/en
Priority to US10/450,345 priority patent/US20040048905A1/en
Priority to KR10-2003-7007578A priority patent/KR20040007420A/en
Priority to SK765-2003A priority patent/SK7652003A3/en
Priority to DK01992150T priority patent/DK1345607T3/en
Priority to CA002432282A priority patent/CA2432282A1/en
Priority to HU0302456A priority patent/HUP0302456A3/en
Priority to CZ20031677A priority patent/CZ301424B6/en
Priority to KR10-2003-7007754A priority patent/KR20030061840A/en
Priority to PT01992150T priority patent/PT1345607E/en
Priority to AU3262002A priority patent/AU3262002A/en
Priority to RU2003121019/15A priority patent/RU2292206C2/en
Priority to SI200130662T priority patent/SI1345607T1/en
Priority to ES01992150T priority patent/ES2272565T3/en
Priority to DE60122928T priority patent/DE60122928T2/en
Priority to SK764-2003A priority patent/SK7642003A3/en
Priority to PL01360989A priority patent/PL360989A1/en
Priority to KR1020097004242A priority patent/KR20090033914A/en
Priority to AU2002232620A priority patent/AU2002232620B9/en
Priority to JP2002550986A priority patent/JP2004519440A/en
Priority to EP01992150A priority patent/EP1345607B1/en
Priority to CNA018208398A priority patent/CN1481241A/en
Priority to IL15626701A priority patent/IL156267A0/en
Priority to NZ526467A priority patent/NZ526467A/en
Priority to BR0116228-4A priority patent/BR0116228A/en
Priority to PCT/US2001/048808 priority patent/WO2002049646A1/en
Priority to MXPA03005463A priority patent/MXPA03005463A/en
Priority to EP06003150A priority patent/EP1674099A1/en
Priority to AT01992150T priority patent/ATE338549T1/en
Publication of WO2002049645A1 publication Critical patent/WO2002049645A1/en
Priority to ZA200304514A priority patent/ZA200304514B/en
Priority to EC2003004658A priority patent/ECSP034658A/en
Priority to NO20032766A priority patent/NO20032766L/en
Priority to NO20032765A priority patent/NO20032765L/en
Priority to HK04100922A priority patent/HK1059566A1/en
Priority to CY20061101728T priority patent/CY1106275T1/en
Priority to IL190802A priority patent/IL190802A0/en
Priority to IL190801A priority patent/IL190801A0/en
Priority to US12/180,979 priority patent/US20080287412A1/en
Priority to JP2009235225A priority patent/JP2010043111A/en
Priority to US12/761,450 priority patent/US20100196467A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • CBs Calcium channel blockers
  • ACEIs angiotensin converting enzyme inhibitors
  • a representative of the class of CCBs is amiodipine, while a representative of the class of ACEIs is benazepril or benazeprilat.
  • Amiodipine is 2-[(2-aminoethoxy)methyl]-4-(2-chIorophenyl)-1 ,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester. It is sold commercially in the form of its besylate salt under the trademark NORVASC® as an antihypertensive. Amiodipine may be administered in free or pharmaceutically aceptable salt form. Where amiodipine dosages are set forth herein, it is understood that the amounts are the amounts corresponding to amiodipine free base equivalents, irrespective of the salt form used, unless otherwise indicated.
  • a chronic anti-hypertensive therapy with amiodipine is often associated with side effects such as dose-limiting peripheral edema, especially ankle edema.
  • the amiodipine induced ankle edema is believed to be due to a preferential dilation of the precapillary arterioles in the leg and a resultant efflux of fluid into the interstitial space.
  • the upper limit of mono-therapy with amiodipine is 10 mg per day, and lower doses are preferred for chronic treatments. Higher dosage formulations than 10 mg per day are not approved by regulatory authorities or marketed, as in many susceptible individuals, side effects, such as those mentioned above, may limit efficacy and may ultimately result in discontinuation of the therapy.
  • a "high dose” or a “higher dose” of amiodipine refers to daily dosage amounts greater than 5 mgs amiodipine, preferably from 6-40 mgs, more preferably 7.5-20 mgs, for example, 7.5, 10, 15, or 20 mgs, more preferably at least 10 mgs, e.g., 10, 12.5, 15, or 20 mgs, most preferably 10 or 20 mgs.
  • dosages of 10-60mgs, preferably 20 to 40 mgs, for example 20, 30, or 40 mgs,, especially 40 mgs, are preferred.
  • Benazepril is [S-(R * ,R * )]-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2- oxo-1 H-1-benazepine-1 -acetic acid. It is sold commercially in the form of the hydrochloride salt under the trademarks LOTENSIN® or CIBACEN® as an antihypertensive. Benazeprilat is the diacid form of benazepril formed by cleavage of the ester group, and is the active metabolite of benazepril. Benazepril and benazeprilat may be administered in free or pharmaceutically acceptable salt form.
  • ACEIs may only be moderately effective in non-Caucasian populations, especially in toe African Americans, and in patients where the renin angiotensin aldosterone system (RAAS) is already suppressed.
  • a "high dose” or a “higher dose” of benazepril” refers to dosage amounts corresponding to greater than 20 mg benazepril hydrochloride, preferably from 21 to 160 mgs, preferably 40 to 80 mgs, for example, 40 mg or 80 mgs. Dosage amounts of this drug may be also be given every other day, in combination with amiodipine on the same day or on alternate days on which the amiodipine is administered. In both cases, the amount of benazepril would be preferably kept constant.
  • amiodipine and benazepril Fixed dose combinations of amiodipine and benazepril are being marketed under the trade name Lotrel®. Corresponding amounts of the active ingredients are 2.5 mg of amiodipine and 10 mg of benazepril, 5 mg of amiodipine and 10 mg of benazepril, and 5 mg of amiodipine and 20 mg of benazepril, the amounts of amiodipine corresponding to the free base and the amounts of benazepril corresponding to the hydrochloride. As used herein, the term “Lotrel® combination" refers to these dosage combinations.
  • the therapeutic combination of amiodipine and benazepril contemplated herein includes administration of these compounds such that the combination of amiodipine and benzapril may be administered every other day.
  • benazepril alone may be administered on the alternate days.
  • patients are provided with dosage forms comprising (i) combinations of amiodipine with benazepril and (ii) dosage forms comprising benazepril as active ingredient or placebo, in which case the two dosage forms may be provided in a kit of parts as described below.
  • packages will comprise daily dosage amounts of appropriate active ingredients in a dispenser, blister pack or with other suitable packaging and instructions to ensure that the appropriate tablets are taken on the alternating days and otherwise ensure proper compliance with a prescribed dosage schedule.
  • a high dose amiodipine may be alternated with lower dosage amounts of this drug on a daily basis in combination with daily administration of benazepril.
  • the daily dosage level of the benazepril in this regime would remain constant.
  • the high dose combination of amiodipine and benazepril or benazeprilate, respectively, as disclosed herein provides some surprising beneficial effects with an overall lack of adverse effects, selected from (but are not limited to) e.g. (i) a greater blood pressure control (either or both of systolic and diastolic blood pressure), especially in patients who do not achieve blood pressure levels defined as normal or optimal according to the WHO guidelines of the management of hypertension; (ii) reduction, prevention, attenuation or delay of side effects associated with amiodipine, such as the dose- limiting formation of peripheral edema, e.g.
  • ankle edema (iii) reduction of afterload; (iv) end- organ protection, especially in case of the treatment of angina; and (v) reduction, prevention, attenuation or delay of risks or incidences of morbidity and mortality, especially of morbidity and mortality associated with atherosclerosis.
  • a preferred patient population for applying the combination according to the present invention is selected from (i) those patients who do not achieve blood pressure levels defined as normal or optimal according to the WHO guidelines of the management of hypertension of 1999 (cf. J Hypertens 1999, 17:151-183); (ii) those patients with angina who require greater control of angina or blood pressure or both; (iii) those patients with heart failure, especially congestive heart failure, who require greater control of blood pressure, and (iv) patients suffering from pulmonary disease or pulmonary hypertension.
  • moderate hypertension being characterized by a DBP of approximately 100 mm Hg according to said WHO definitions
  • Corresponding clinical trials can be carried out e.g. in a double-blind, randomized, placebo- controlled, forced-titration, parallel-group trial.
  • patients are randomized to receive either a Lotrel ® combination (e.g. 5 mg of amiodipine corresponding of the free base and 20 mg of benazepril corresponding to the hydrochloride) or a combination according to the present invention (e.g. 10 mg of amiodipine corresponding of the free base and 20 mg of benazepril corresponding to the free base) for 6 weeks; patients receiving placebo remain on placebo for the entire 8 weeks.
  • the efficacy e.g. the change of blood pressure from baseline to the endpoint, is to be determined as well as the safety, e.g. the incidence of potential side effects.
  • the combination according to the present invention can be used for the treatment (acute and especially chronic treatment) or prevention or delay of progression of a condition selected from the group consisting of hypertension (whether of the malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type), heart failure, such as congestive heart failure, angina (whether stable or unstable), myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular dysfunction, such as left ventricular hypertrophy, cognitive dysfunction (such as Alzheimer's, etc.), blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache.
  • hypertension whether of the malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type
  • heart failure such as congestive heart failure
  • angina whether stable or unstable
  • myocardial infarction atherosclerosis
  • diabetic nephropathy diabetic
  • amiodipine can be used, likewise, for the prevention, reduction, attenuation and delay of progression of side effects associated with high dose application of amiodipine; and for the protection of end-organs, including the kidneys and the heart, for example protection against left ventricular hypertrophy, right ventricular hypertrophy, e.g. as associated with pulmonary hypertension, and the like.
  • the present invention relates to the use of a combination comprising
  • an ACE inhibitor selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
  • amiodipine or pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein
  • the amount of amiodipine or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 6 mg to 40 mg of the free base and
  • the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 20 mg to 160 mg of benazepril hydrochloride.
  • the invention likewise relates to a composition, such as a pharmaceutical composition e.g. for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary hypertension, and headache; comprising
  • an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
  • the amount of amiodipine or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 6 mg to about 40 mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof is a high dose as defined above, e.g., corresponding to 20 mg to 160 mg of benazepril hydrochloride.
  • Fixed combinations of amiodipine and benazepril in accordance with the present invention thus include combinations of high dose amiodipine and high dose benazepril, in ranges as described above, and also combinations at higher dosages of amiodipine than currently approved and provided in Lotrel® combinations, for example combinations containing amounts corresponding to 10-60 mg amiodipine and 20-160 mgs benazepril, e.g., combintations corresponding to (i)10-40 mgs amiodipine ree base, e.g., 10, 15 or 20 mgs, and (ii) 20-80 mgs benazepril hydrochloride, for example combinations corresponding to 10mg amolodipine free base and 20 mgs benazepril HCI, 10 mg amiodipine free base and 40 mgs benazepril HCI, 20 mgs amiodipine free base and 40 mgs benzapril HCI, and 20 mgs amiodipine free base and
  • amolidpine is preferably in the form of amiodipine besylate.
  • the benazepril is preferably in the form of benazepril hydrochloride.
  • pharmaceutically acceptable carrier includes compounds well known to one of skill in the art and comprises excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
  • the present invention likewise relates to a method of treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache, comprising administering to a warm-blooded animal including man in need thereof an effective amount of a combination comprising
  • an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
  • the amount of amiodipine or a pharmaceutically acceptable salt thereof in a high dose as defined above e.g., corresponding to 6 mg to about 40 mg free base
  • the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is a high does as defined above, e.g., corresponding to 20 mg to 160 mg benazepril hydrochloride.
  • the corresponding active ingredients or a pharmaceutically acceptable salt thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization according to conventional methods.
  • the compounds to be combined can be present as pharmaceutically acceptable salts. As these compounds have at least one basic center, they can form acid addition salts.
  • a preferred pharmaceutically acceptable salt of amiodipine is the besylate salt being the subject matter of US Patent 4,879,303; furthermore the maleate salt as set forth in US Patent 4,572,909; both patents are incorporated by reference herein in their entirety.
  • the ACEI is benazepril or a salt thereof, most preferably the hydrochloride thereof.
  • Suitable salts of benazepril and benazeprilat can be found in US Patent No. 4,410,520 and which is incorporated by reference herein in its entirety.
  • the hydrochloride salt of the ACEI is most advantageous, with the most preferred specific ACEI compound being benazepril hydrochloride.
  • the most preferred active components according to the instant invention are amiodipine besylate and benazepril hydrochloride.
  • Preferred dosage ranges in combinations according to the instant invention comprise an amount of amiodipine or a pharmaceutically acceptable salt thereof from 6 mg to 40 mg and an amount of the ACEI or a pharmaceutically acceptable salt thereof from 20 mg to 160 mg, in each case, corresponding to the free base.
  • the amount of amiodipine or a pharmaceutically acceptable salt thereof is preferably from 6 mg to 20 mg, especially 10 mg, in all above cases, corresponding to the free base.
  • a preferred amount of benazepril or benazeprilat, respectively, or, in each case, pharmaceutically acceptable salt thereof is from 20 mg to 80 mg, preferably 20 mg to 40 mg, e.g., 20, 30, or 40 mgs, especially 20 mgs, or from 40 mg to 160 mg, especially 40 mg to 120 mg, most preferably 40 mg to 80 mg, , e.g., 40, 50, 60 70 or 80 mgs, esp. 40 mgs; in all above cases, corresponding to benazepril hydrochloride.
  • a preferred amount of amiodipine or a pharmaceutically acceptable salt thereof is 10 or 20 mg and preferred amounts of benazepril or a pharmaceutically acceptable salt thereof are 20 mg, 40 mg or 80 mg. Most preferably all said doses are daily doses.
  • a "daily dose” refers to the total amount of the drug substance administered in a 24 hour period, with a single administration the preferred method of treatment.
  • the active ingredients of the pharmaceutical composition according to the present invention as described herein may be used for simultaneous use or sequential use in any order, for separate use or most preferably as a fixed combination.
  • the CCB and the ACEI can be administered at different times, they are most preferably administered at the same time. Most conveniently, this is via a single, fixed combination dosage form. However, the CCB can be administered at times different from the administration of the ACEI and the invention benefits still be realized. When administered at different times, the CCB and the ACEI should be given within about 16 hours of each other, preferably within about 12 hours of each other, more preferably within about 8 hours of each other, most preferably within about 4 hours of each other. Of course, these time periods can be extended if the dosage form is one that will "administer" the agents for extended periods.
  • the CCB and the ACEI When the CCB and the ACEI are given substantially simultaneously, they may be given by a single fixed combination dosage form or by different dosage forms, whichever are convenient. When given by different dosage forms, it is irrelevant whether the route of administration is the same for each agent or different for each agent. Any route of administration known for the individual agents is acceptable for the practice of the present invention. Most preferably, the agents are given in a fixed combination, or at least substantially simultaneously, i.e. within about 1 hour of each other. Also, the most suitable dosage form is an oral dosage form, where an oral administration is a clinically suitable route.
  • the present invention likewise relates to a "kit-of-parts", for example, in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points.
  • the parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
  • the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is more beneficial than the effect that would be obtained by use of only any one of the components.
  • Dosages of the two agents include all dosages at which the agents are used individually.
  • Corresponding dosages for other salts of amiodipine, for free benazepril and other salts of benazepril, and benazeprilat and its salts will be readily apparent to those of ordinary skill in the art.
  • the range is the acceptable range based on adult mammal of approximately 50 to about 70 kg. Modified dosage ranges for mammals of other sizes and stages of development will be apparent to those of ordinary skill in the art.
  • Benazepril and amiodipine are normally physically incompatible substances. Hence, if incorporated into a single dosage form they must be kept physically separated.
  • preferred mammals are rabbits, dogs, goats, hogs, sheep, horses, cattle, and primates, more preferably primates, most preferably humans.
  • the invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.
  • Benazepril hydrochloride cores are prepared using the following:
  • Components 1-3 are milled and blended together and water is added to granulate the blend.
  • the wet granules are screened and oven dried.
  • the dried granules are then milled together with components 5-7.
  • Component 4 is screened and then mixed with the other ingredients. The resulting mixture is then compressed into a core.
  • Component 10 is dissolved in the water and component 9 is added thereto.
  • the previously made cores are then coated with this solution and the wet coated tablets are dried. The dried tablets are then dusted with component 12.
  • Amiodipine besylate for incorporation into the formulation is prepared as follows:
  • Components 13-16 are mixed together and the blended mixture is screened and reblended.
  • Component 17 is separately screened and then blended with the reblended mixture containing the amiodipine.
  • No. 1 hard gelatin capsules are used to encapsulate one benazepril hydrochloride containing coated core along with 200 mg of the amiodipine besylate containing powder per capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention especially relates to the use of a combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and (2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein (i) the amount of amlodipine or a phamaceutically acceptable salt thereof corresponds to 6 mg to 40 mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 mg to 160 mg of benazepril hydrochloride.

Description

THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL
Calcium channel blockers (CCBs) and angiotensin converting enzyme inhibitors (ACEIs) are widely used for the treatment of hypertension and related diseases and conditions. A representative of the class of CCBs is amiodipine, while a representative of the class of ACEIs is benazepril or benazeprilat.
Amiodipine is 2-[(2-aminoethoxy)methyl]-4-(2-chIorophenyl)-1 ,4-dihydro-6-methyl-3,5- pyridinedicarboxylic acid 3-ethyl 5-methyl ester. It is sold commercially in the form of its besylate salt under the trademark NORVASC® as an antihypertensive. Amiodipine may be administered in free or pharmaceutically aceptable salt form. Where amiodipine dosages are set forth herein, it is understood that the amounts are the amounts corresponding to amiodipine free base equivalents, irrespective of the salt form used, unless otherwise indicated.
It is known that a chronic anti-hypertensive therapy with amiodipine is often associated with side effects such as dose-limiting peripheral edema, especially ankle edema. The amiodipine induced ankle edema, for example, is believed to be due to a preferential dilation of the precapillary arterioles in the leg and a resultant efflux of fluid into the interstitial space. The upper limit of mono-therapy with amiodipine is 10 mg per day, and lower doses are preferred for chronic treatments. Higher dosage formulations than 10 mg per day are not approved by regulatory authorities or marketed, as in many susceptible individuals, side effects, such as those mentioned above, may limit efficacy and may ultimately result in discontinuation of the therapy. As used herein, a "high dose" or a "higher dose" of amiodipine refers to daily dosage amounts greater than 5 mgs amiodipine, preferably from 6-40 mgs, more preferably 7.5-20 mgs, for example, 7.5, 10, 15, or 20 mgs, more preferably at least 10 mgs, e.g., 10, 12.5, 15, or 20 mgs, most preferably 10 or 20 mgs. For administration every other day, dosages of 10-60mgs, preferably 20 to 40 mgs, for example 20, 30, or 40 mgs,, especially 40 mgs, are preferred.
Benazepril is [S-(R*,R*)]-3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2- oxo-1 H-1-benazepine-1 -acetic acid. It is sold commercially in the form of the hydrochloride salt under the trademarks LOTENSIN® or CIBACEN® as an antihypertensive. Benazeprilat is the diacid form of benazepril formed by cleavage of the ester group, and is the active metabolite of benazepril. Benazepril and benazeprilat may be administered in free or pharmaceutically acceptable salt form. Where benazepril dosages are set forth herein, it is understood that the are the amounts are amounts of benazepril or benazeprilat corresponding to benazepril hydrochloride equivalents, irrespective of the actual salt form used, unless otherwise indicated.
The therapy using benazepril or a pharmaceutically acceptable salt thereof or benazeprilat ranges from 10 mg to 80 mg per day. However, ACEIs may only be moderately effective in non-Caucasian populations, especially in toe African Americans, and in patients where the renin angiotensin aldosterone system (RAAS) is already suppressed. As used herein, a "high dose" or a "higher dose" of benazepril" refers to dosage amounts corresponding to greater than 20 mg benazepril hydrochloride, preferably from 21 to 160 mgs, preferably 40 to 80 mgs, for example, 40 mg or 80 mgs. Dosage amounts of this drug may be also be given every other day, in combination with amiodipine on the same day or on alternate days on which the amiodipine is administered. In both cases, the amount of benazepril would be preferably kept constant.
Fixed dose combinations of amiodipine and benazepril are being marketed under the trade name Lotrel®. Corresponding amounts of the active ingredients are 2.5 mg of amiodipine and 10 mg of benazepril, 5 mg of amiodipine and 10 mg of benazepril, and 5 mg of amiodipine and 20 mg of benazepril, the amounts of amiodipine corresponding to the free base and the amounts of benazepril corresponding to the hydrochloride. As used herein, the term "Lotrel® combination" refers to these dosage combinations.
There is a clear need to provide a combination comprising a higher amount of the CCB and/or of the ACEI showing not only a greater blood pressure control, but also showing unexpected and even more beneficial advantages over lower dose combinations of amiodipine and benazepril. Such advantages comprise using such a combination in chronic treatment, e.g. avoiding side effects associated with high doses of amiodipine, in achieving further beneficial effects. Surprisingly, administration of a high dose combination of amiodipine and benazepril exhibits even more beneficial advantages over the known low dose combinations that are being marketed.
The therapeutic combination of amiodipine and benazepril contemplated herein includes administration of these compounds such that the combination of amiodipine and benzapril may be administered every other day. Optionally, when the combination is administered every other day, benazepril alone may be administered on the alternate days. Suitably, patients are provided with dosage forms comprising (i) combinations of amiodipine with benazepril and (ii) dosage forms comprising benazepril as active ingredient or placebo, in which case the two dosage forms may be provided in a kit of parts as described below. For example, packages will comprise daily dosage amounts of appropriate active ingredients in a dispenser, blister pack or with other suitable packaging and instructions to ensure that the appropriate tablets are taken on the alternating days and otherwise ensure proper compliance with a prescribed dosage schedule. In a related embodiment, a high dose amiodipine may be alternated with lower dosage amounts of this drug on a daily basis in combination with daily administration of benazepril. Typically, the daily dosage level of the benazepril in this regime would remain constant.
The high dose combination of amiodipine and benazepril or benazeprilate, respectively, as disclosed herein provides some surprising beneficial effects with an overall lack of adverse effects, selected from (but are not limited to) e.g. (i) a greater blood pressure control (either or both of systolic and diastolic blood pressure), especially in patients who do not achieve blood pressure levels defined as normal or optimal according to the WHO guidelines of the management of hypertension; (ii) reduction, prevention, attenuation or delay of side effects associated with amiodipine, such as the dose- limiting formation of peripheral edema, e.g. ankle edema; (iii) reduction of afterload; (iv) end- organ protection, especially in case of the treatment of angina; and (v) reduction, prevention, attenuation or delay of risks or incidences of morbidity and mortality, especially of morbidity and mortality associated with atherosclerosis.
A preferred patient population for applying the combination according to the present invention is selected from (i) those patients who do not achieve blood pressure levels defined as normal or optimal according to the WHO guidelines of the management of hypertension of 1999 (cf. J Hypertens 1999, 17:151-183); (ii) those patients with angina who require greater control of angina or blood pressure or both; (iii) those patients with heart failure, especially congestive heart failure, who require greater control of blood pressure, and (iv) patients suffering from pulmonary disease or pulmonary hypertension.
These surprising and beneficial effects can be proven by carrying out appropriate clinical trials or experiments in conventional animal test models.
For example, in clinical trials when administering a combination according to the present invention, a positive dose response is demonstrated, reduced side effects are observed and a more pronounced blood pressure lowering effect is observed in patients with different categories of hypertension, such as severe hypertension, as compared to a Lotrel® combination. (According to the WHO, patients who have a systolic blood pressure (SBP) of ≥ 180 mm Hg or a diastolic blood pressure (DBP) of ≥ 110 mm Hg or patients who have both SBP of ≥ 180 mm Hg and DBP of ≥ 110 mm Hg have severe hypertension.) Likewise, patients with essential hypertension (MSBBP ≥ 95 mm Hg to ≤ 115 mm Hg) who have received the combination according to the present invention have a greater responder rate than those patients who receive a Lotrel® combination. Especially beneficial is the treatment of patients with moderate to severe hypertension (moderate hypertension being characterized by a DBP of approximately 100 mm Hg according to said WHO definitions), most preferable is treatment of patients with severe hypertension (e.g. mean sitting diastolic blood pressure = MSDBP > 105 mm Hg at baseline).
Corresponding clinical trials can be carried out e.g. in a double-blind, randomized, placebo- controlled, forced-titration, parallel-group trial. For example, following a 2-week washout period and a 2-week single-blind placebo run-in period, patients are randomized to receive either a Lotrel ® combination (e.g. 5 mg of amiodipine corresponding of the free base and 20 mg of benazepril corresponding to the hydrochloride) or a combination according to the present invention (e.g. 10 mg of amiodipine corresponding of the free base and 20 mg of benazepril corresponding to the free base) for 6 weeks; patients receiving placebo remain on placebo for the entire 8 weeks. The efficacy, e.g. the change of blood pressure from baseline to the endpoint, is to be determined as well as the safety, e.g. the incidence of potential side effects.
The combination according to the present invention can be used for the treatment (acute and especially chronic treatment) or prevention or delay of progression of a condition selected from the group consisting of hypertension (whether of the malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type), heart failure, such as congestive heart failure, angina (whether stable or unstable), myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular dysfunction, such as left ventricular hypertrophy, cognitive dysfunction (such as Alzheimer's, etc.), blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache. It can be used, likewise, for the prevention, reduction, attenuation and delay of progression of side effects associated with high dose application of amiodipine; and for the protection of end-organs, including the kidneys and the heart, for example protection against left ventricular hypertrophy, right ventricular hypertrophy, e.g. as associated with pulmonary hypertension, and the like.
The present invention relates to the use of a combination comprising
(1) an ACE inhibitor, selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 6 mg to 40 mg of the free base and
(ii) the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 20 mg to 160 mg of benazepril hydrochloride. The invention likewise relates to a composition, such as a pharmaceutical composition e.g. for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary hypertension, and headache; comprising
(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, and
(3) a pharmaceutically acceptable carrier; wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof is a high dose as defined above, e.g., corresponding to 6 mg to about 40 mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof is a high dose as defined above, e.g., corresponding to 20 mg to 160 mg of benazepril hydrochloride.
Fixed combinations of amiodipine and benazepril in accordance with the present invention thus include combinations of high dose amiodipine and high dose benazepril, in ranges as described above, and also combinations at higher dosages of amiodipine than currently approved and provided in Lotrel® combinations, for example combinations containing amounts corresponding to 10-60 mg amiodipine and 20-160 mgs benazepril, e.g., combintations corresponding to (i)10-40 mgs amiodipine ree base, e.g., 10, 15 or 20 mgs, and (ii) 20-80 mgs benazepril hydrochloride, for example combinations corresponding to 10mg amolodipine free base and 20 mgs benazepril HCI, 10 mg amiodipine free base and 40 mgs benazepril HCI, 20 mgs amiodipine free base and 40 mgs benzapril HCI, and 20 mgs amiodipine free base and 80 mgs benazepril HCI.
The amolidpine is preferably in the form of amiodipine besylate. The benazepril is preferably in the form of benazepril hydrochloride.
As used herein, "pharmaceutically acceptable carrier" includes compounds well known to one of skill in the art and comprises excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
The present invention likewise relates to a method of treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache, comprising administering to a warm-blooded animal including man in need thereof an effective amount of a combination comprising
(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof in a high dose as defined above, e.g., corresponding to 6 mg to about 40 mg free base and (ii) the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof is a high does as defined above, e.g., corresponding to 20 mg to 160 mg benazepril hydrochloride.
The corresponding active ingredients or a pharmaceutically acceptable salt thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization according to conventional methods.
The compounds to be combined can be present as pharmaceutically acceptable salts. As these compounds have at least one basic center, they can form acid addition salts.
A preferred pharmaceutically acceptable salt of amiodipine is the besylate salt being the subject matter of US Patent 4,879,303; furthermore the maleate salt as set forth in US Patent 4,572,909; both patents are incorporated by reference herein in their entirety. Preferably, the ACEI is benazepril or a salt thereof, most preferably the hydrochloride thereof. Suitable salts of benazepril and benazeprilat can be found in US Patent No. 4,410,520 and which is incorporated by reference herein in its entirety. For purposes of the present invention, the hydrochloride salt of the ACEI is most advantageous, with the most preferred specific ACEI compound being benazepril hydrochloride.
The most preferred active components according to the instant invention are amiodipine besylate and benazepril hydrochloride.
Preferred dosage ranges in combinations according to the instant invention comprise an amount of amiodipine or a pharmaceutically acceptable salt thereof from 6 mg to 40 mg and an amount of the ACEI or a pharmaceutically acceptable salt thereof from 20 mg to 160 mg, in each case, corresponding to the free base. Within such combinations the amount of amiodipine or a pharmaceutically acceptable salt thereof is preferably from 6 mg to 20 mg, especially 10 mg, in all above cases, corresponding to the free base. A preferred amount of benazepril or benazeprilat, respectively, or, in each case, pharmaceutically acceptable salt thereof is from 20 mg to 80 mg, preferably 20 mg to 40 mg, e.g., 20, 30, or 40 mgs, especially 20 mgs, or from 40 mg to 160 mg, especially 40 mg to 120 mg, most preferably 40 mg to 80 mg, , e.g., 40, 50, 60 70 or 80 mgs, esp. 40 mgs; in all above cases, corresponding to benazepril hydrochloride.
A preferred amount of amiodipine or a pharmaceutically acceptable salt thereof is 10 or 20 mg and preferred amounts of benazepril or a pharmaceutically acceptable salt thereof are 20 mg, 40 mg or 80 mg. Most preferably all said doses are daily doses. As used herein, a "daily dose" refers to the total amount of the drug substance administered in a 24 hour period, with a single administration the preferred method of treatment.
The active ingredients of the pharmaceutical composition according to the present invention as described herein may be used for simultaneous use or sequential use in any order, for separate use or most preferably as a fixed combination.
While the CCB and the ACEI can be administered at different times, they are most preferably administered at the same time. Most conveniently, this is via a single, fixed combination dosage form. However, the CCB can be administered at times different from the administration of the ACEI and the invention benefits still be realized. When administered at different times, the CCB and the ACEI should be given within about 16 hours of each other, preferably within about 12 hours of each other, more preferably within about 8 hours of each other, most preferably within about 4 hours of each other. Of course, these time periods can be extended if the dosage form is one that will "administer" the agents for extended periods.
When the CCB and the ACEI are given substantially simultaneously, they may be given by a single fixed combination dosage form or by different dosage forms, whichever are convenient. When given by different dosage forms, it is irrelevant whether the route of administration is the same for each agent or different for each agent. Any route of administration known for the individual agents is acceptable for the practice of the present invention. Most preferably, the agents are given in a fixed combination, or at least substantially simultaneously, i.e. within about 1 hour of each other. Also, the most suitable dosage form is an oral dosage form, where an oral administration is a clinically suitable route.
In a variation thereof, the present invention likewise relates to a "kit-of-parts", for example, in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points. The parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Preferably, the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is more beneficial than the effect that would be obtained by use of only any one of the components.
Dosages of the two agents include all dosages at which the agents are used individually. Corresponding dosages for other salts of amiodipine, for free benazepril and other salts of benazepril, and benazeprilat and its salts will be readily apparent to those of ordinary skill in the art. In each of the dosages set forth here, the range is the acceptable range based on adult mammal of approximately 50 to about 70 kg. Modified dosage ranges for mammals of other sizes and stages of development will be apparent to those of ordinary skill in the art. Benazepril and amiodipine are normally physically incompatible substances. Hence, if incorporated into a single dosage form they must be kept physically separated. This may be accomplished in any of the myriad ways known in the art, such as bi-layered tablets, coated pellets of one agent incorporated into a tablet of the other, separately coated pellets of each agent in a capsule or tablet, coated pellets of one agent in capsule together with powder of the other agent, each agent microencapsulated separately and then blended together for use in a tablet or capsule, use of a dual or multiple compartment transdermal device, etc. Due to the incompatibility, combination products of the two agents in an injectable solution may not really be acceptable. For convenience purposes, a coated compressed tablet of benazepril together with amiodipine powder in a capsule has been found to be the most desirable oral form.
For the present purposes, preferred mammals are rabbits, dogs, goats, hogs, sheep, horses, cattle, and primates, more preferably primates, most preferably humans.
The invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.
The following examples are presented to exemplify, but not to limit the invention.
Example 1
One thousand capsules containing 40 mg of benazepril hydrochloride and amiodipine besylate equivalent to 10 mg of amiodipine base for use in the present invention were prepared as follows: Benazepril hydrochloride cores are prepared using the following:
1. Benazepril HCL 40.000 g
2. Lactose, monohydrate 32.920 g
3. Pregelatinized Starch 5.000 g
4. Colloidal SiO2 1.000 g
5. Crospovidine 2.000 g
6. Microcrystalline Cellulose 10.000 g
7. Hydrogenated Castor Oil 4.000 g 8. Purified Water as needed
Components 1-3 are milled and blended together and water is added to granulate the blend. The wet granules are screened and oven dried. The dried granules are then milled together with components 5-7. Component 4 is screened and then mixed with the other ingredients. The resulting mixture is then compressed into a core.
The thus made cores are coated with a coating solution prepared as follows: 9. Hydroxypropyl Methylcellulose
2910, 3cps 4.881 g
10. Polysorbate 80 0.119 g
11. Purified Water as needed
12. Talc trace
Component 10 is dissolved in the water and component 9 is added thereto. The previously made cores are then coated with this solution and the wet coated tablets are dried. The dried tablets are then dusted with component 12.
Amiodipine besylate for incorporation into the formulation is prepared as follows:
13. Amiodipine Besylate 13.888 g
14. Microcrystalline Cellulose 124.056 g
15. Calcium Phosphate Dibasic 63.000 g
16. Sodium Starch Glycolate 4.000 g
17. Magnesium Stearate 2.000 g
Components 13-16 are mixed together and the blended mixture is screened and reblended. Component 17 is separately screened and then blended with the reblended mixture containing the amiodipine.
No. 1 hard gelatin capsules are used to encapsulate one benazepril hydrochloride containing coated core along with 200 mg of the amiodipine besylate containing powder per capsule.

Claims

What is claimed is
1. The use of a combination comprising
(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof is corresponds to 6 mg to 40 mg of the free base and
(ii) the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof corresponds to 20 mg to 160 mg of benazepril hydrochloride.
2. Use according to claim 1 the amiodipine is amiodipine besylate.
3. Use according to claim 1 or 2 wherein the benazepril is benazepril hydrochloride.
4. Use according to any one of claims 1 to 3 wherein the amiodipine is amiodipine besylate and the benazepril is benazepril hydrochloride.
5. Use according to any one of claims 1 to 4 wherein the amount of amiodipine or a pharmaceutically acceptable salt thereof corresponds to from 6 mg to 20 mg of the free base.
6. Use according to any one of claims 1 to 5 wherein the amount of benazepril or a pharmaceutically acceptable salt thereof corresponds to 20 mg to 40 mg of benazepril hydrochloride.
7. Use according to any one of claims 1 to 6 wherein the amount of benazepril or a pharmaceutically acceptable salt thereof corresponds to from 40 mg to 80 mg of benazepril hydrochloride.
8. Use according to any one of claims 1 to 7 wherein the amiodipine or a pharmaceutically acceptable salt thereof and the benazepril or a pharmaceutically acceptable salt thereof are administered in a single dosage form, such that the amiodipine and the benazepril are physically separated from each other.
9. A pharmaceutical composition for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, atherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke pulmonary disease or pulmonary hypertension and headache; comprising
(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, and
(3) a pharmaceutically acceptable carrier; wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof corresponds to 6 mg to about 40 mg of the free base and
(ii) the amount of the ACE inhibitor or a pharmaceutically acceptable salt thereof corresponds to 20 mg to 160 mg of benazepril hydrochloride.
10. Composition according to claim 9 wherein the amiodipine is amiodipine besylate.
11. Composition according to claim 9 and 10 wherein the benazepril is benazepril hydrochloride.
12. Composition according to any one of claims 9 to 11 wherein the amiodipine is amiodipine besylate and the benazepril is benazepril hydrochloride.
13. Composition according to any one of claims 9 to 12 wherein the amount of amiodipine or a pharmaceutically acceptable salt thereof corresponds to from 6 mg to 20 mg of amiodipine free base; and wherein the amount of benazepril or a pharmaceutically acceptable salt thereof is selected from an amount corresponding to 20 mg to 40 mg, from 40 mg to 80 mg, and from 80 mg to120 mg of benazepril hydrochloride.
14. Composition according to any one of claims 9 to 13 for simultaneous use or sequential use in any order, for separate use or most preferably as a fixed combination.
15. Composition according to any one of claims 9 to 14 wherein the amiodipine and the benazepril are administered in a single dosage form, such that the amiodipine and the benazepril are physically separated from each other.
16. Composition according to any one of claims 9 to 15 wherein the single dosage form comprises a capsule comprising within it (a) amiodipine powder and (b) a coated compressed tablet of benazepril.
17. Composition according to any one of claims 9 to 16 wherein the amiodipine or a pharmaceutically acceptable salt thereof is administered in a second formulation that is free of the benazepril or a pharmaceutically acceptable salt thereof and the benazepril is administered in a first formulation that is free of the amiodipine.
18. Composition according to any one of claims 9 to 17 wherein said first formulation and said second formulation are administered within about one hour of each other.
19. Composition according to any one of claims 9 to 18 wherein the amount of amiodipine or a pharmaceutically acceptable salt thereof and benazepril or a pharmaceutically acceptable salt thereof, in each case, is the daily dosage.
20. A commercial package comprising the composition according to any one of claims 9 to 19 together with instructions for simultaneous, separate or sequential use.
21. A combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and
(2) amiodipine or pharmaceutically acceptable salt thereof, wherein
(i) the amount of amiodipine or a pharmaceutically acceptable salt thereof corresponds to 6 mg to 40 mg of the free base and
(ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 mg to 160 mg of benazepril hydrochloride.
PCT/US2000/034246 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril WO2002049645A1 (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
NZ526385A NZ526385A (en) 2000-12-18 2000-12-18 High dose therapeutic combination of amlodipine and benazepril
JP2002550985A JP2004516266A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazebril
CZ20031678A CZ20031678A3 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
HU0302455A HUP0302455A3 (en) 2000-12-18 2000-12-18 Combination pharmaceutical compositions containing amplodipine and benazepril and their use
PL00362252A PL362252A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
MXPA03005462A MXPA03005462A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril.
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
BR0017386-0A BR0017386A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
AU2001225816A AU2001225816B2 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
EP00989288A EP1365761A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
CN00820080A CN1461218A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
CA002432638A CA2432638A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
IL15613600A IL156136A0 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
AU2581601A AU2581601A (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
US10/450,345 US20040048905A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
KR10-2003-7007578A KR20040007420A (en) 2000-12-18 2000-12-18 Therapeutic combination of Amlodipine and Benazepril
SK765-2003A SK7652003A3 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
DK01992150T DK1345607T3 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
CA002432282A CA2432282A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
HU0302456A HUP0302456A3 (en) 2000-12-18 2001-12-17 Combination pharmaceutical compositions containing of amlodipine and benazepril and their use and preparation
CZ20031677A CZ301424B6 (en) 2000-12-18 2001-12-17 Use of a combination comprising ACE-inhibitor selected from a group comprising benazepril, benazeprilat, and pharmaceutically acceptable salts thereof
KR10-2003-7007754A KR20030061840A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
PT01992150T PT1345607E (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
AU3262002A AU3262002A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
RU2003121019/15A RU2292206C2 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilate
SI200130662T SI1345607T1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
ES01992150T ES2272565T3 (en) 2000-12-18 2001-12-17 THERAPEUTIC COMBINATION OF AMLODIPINA AND BENAZEPRIL / BENAZEPRILAT.
DE60122928T DE60122928T2 (en) 2000-12-18 2001-12-17 THERAPEUTIC COMPOSITION OF AMLODIPIN AND BENAZEPRIL / BENAZEPRILATE
SK764-2003A SK7642003A3 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
PL01360989A PL360989A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
KR1020097004242A KR20090033914A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
AU2002232620A AU2002232620B9 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
JP2002550986A JP2004519440A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
EP01992150A EP1345607B1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
CNA018208398A CN1481241A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
IL15626701A IL156267A0 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
NZ526467A NZ526467A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat for treating hypertension, cardiocascular diseases and headaches
BR0116228-4A BR0116228A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
PCT/US2001/048808 WO2002049646A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat
MXPA03005463A MXPA03005463A (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat.
EP06003150A EP1674099A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril / benazeprilat
AT01992150T ATE338549T1 (en) 2000-12-18 2001-12-17 THERAPEUTIC COMPOSITION OF AMLODIPINE AND BENAZEPRIL / BENAZEPRILATE
ZA200304514A ZA200304514B (en) 2000-12-18 2003-06-10 Therapeutic combination of amlodipine and benazepril/benazerprilat.
EC2003004658A ECSP034658A (en) 2000-12-18 2003-06-17 THERAPEUTIC COMBINATION OF AMLODIPINA AND BENAZEPRIL / BENAZEPRILATO
NO20032766A NO20032766L (en) 2000-12-18 2003-06-17 Therapeutic compound of amlodipine and benazepril
NO20032765A NO20032765L (en) 2000-12-18 2003-06-17 Therapeutic compound of amlodipine and benazepril / benazeprilat
HK04100922A HK1059566A1 (en) 2000-12-18 2004-02-11 Therapeutic combination of amlodipine and benazepril/benazeprilat
CY20061101728T CY1106275T1 (en) 2000-12-18 2006-11-30 THERAPEUTIC COMBINATION OF AMLODIPINE AND BENAZEPRIL / BENAZEPRILAT
IL190802A IL190802A0 (en) 2000-12-18 2008-04-10 Therapeutic combination of amlodipine and benazepril/benazeprilat
IL190801A IL190801A0 (en) 2000-12-18 2008-04-10 Therapeutic combination of amlodipine and benazepril/benazeprilat
US12/180,979 US20080287412A1 (en) 2000-12-18 2008-07-28 Therapeutic combination of amlodipine and benazepril/benazeprilat
JP2009235225A JP2010043111A (en) 2000-12-18 2009-10-09 Therapeutic combination of amlodipine and benazepril/benazeprilat
US12/761,450 US20100196467A1 (en) 2000-12-18 2010-04-16 Therapeutic combination of amlodipine and benazepril/benazeprilat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/450,344 Continuation US20040062787A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipineand benazepril/benazeprilat
PCT/US2001/048808 Continuation WO2002049646A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat

Publications (1)

Publication Number Publication Date
WO2002049645A1 true WO2002049645A1 (en) 2002-06-27

Family

ID=21742073

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/034246 WO2002049645A1 (en) 2000-12-18 2000-12-18 Therapeutic combination of amlodipine and benazepril
PCT/US2001/048808 WO2002049646A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048808 WO2002049646A1 (en) 2000-12-18 2001-12-17 Therapeutic combination of amlodipine and benazepril/benazeprilat

Country Status (27)

Country Link
EP (3) EP1365761A1 (en)
JP (3) JP2004516266A (en)
KR (3) KR20040007420A (en)
CN (2) CN1461218A (en)
AT (1) ATE338549T1 (en)
AU (4) AU2581601A (en)
BR (2) BR0017386A (en)
CA (2) CA2432638A1 (en)
CY (1) CY1106275T1 (en)
CZ (2) CZ20031678A3 (en)
DE (1) DE60122928T2 (en)
DK (1) DK1345607T3 (en)
EC (1) ECSP034658A (en)
ES (1) ES2272565T3 (en)
HK (1) HK1059566A1 (en)
HU (2) HUP0302455A3 (en)
IL (4) IL156136A0 (en)
MX (2) MXPA03005462A (en)
NO (2) NO20032765L (en)
NZ (1) NZ526467A (en)
PL (2) PL362252A1 (en)
PT (1) PT1345607E (en)
RU (1) RU2292206C2 (en)
SI (1) SI1345607T1 (en)
SK (2) SK7652003A3 (en)
WO (2) WO2002049645A1 (en)
ZA (1) ZA200304514B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043615A2 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
WO2004075856A2 (en) * 2003-02-24 2004-09-10 Novacardia, Inc. Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
WO2005037278A2 (en) * 2003-10-20 2005-04-28 Novartis Ag Tbenazpril and amlodipine for reducing cardiovascular morbidity
WO2005074927A1 (en) * 2004-02-09 2005-08-18 Novartis Ag Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension
WO2005079772A2 (en) * 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
WO2007040511A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1797885A1 (en) * 2005-09-28 2007-06-20 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7579331B2 (en) 2003-04-25 2009-08-25 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
US10874618B2 (en) 2011-12-21 2020-12-29 Elanco Tiergesundheit Ag Compositions for treatment of heart failure in dogs

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
WO2006092732A2 (en) * 2005-03-04 2006-09-08 Aurobindo Pharma Ltd Stable solid dosage form of antihypertensive agent
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
SE534111C2 (en) * 2009-09-14 2011-05-03 Scania Cv Ab Method and system for controlling a coupling
IT1398168B1 (en) * 2010-02-16 2013-02-14 Chiesi Farma Spa USE OF ACTIVE INGREDIENTS IN COMBINATION FOR THE TREATMENT OF COMPLICATIONS OF DIABETES.
EP2585051B2 (en) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
CN102389431A (en) * 2011-09-28 2012-03-28 济南龙华医药技术有限公司 Compound preparation containing benidipine hydrochloride and benazepril hydrochloride, as well as application thereof
ES2924478T3 (en) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulation of pharmaceutical tablets for the veterinary medical sector, method of production and use thereof
JP2015529206A (en) * 2012-08-25 2015-10-05 ザ・ジョンズ・ホプキンス・ユニバーシティ GAPDH cascade inhibitor compounds and methods of use and treatment of stress-induced disorders including psychosis
MX2016000727A (en) 2013-07-19 2016-04-13 Boehringer Ingelheim Vetmed Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition.
CN110721164B (en) 2013-12-04 2024-09-17 勃林格殷格翰动物保健有限公司 Improved pharmaceutical compositions of pimobendan
CA3015964C (en) * 2016-03-24 2021-08-03 Daiichi Sankyo Company, Limited Medicine for treating renal disease
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
ES2900016T3 (en) 2016-11-16 2022-03-15 H Lundbeck As A crystalline form of a MAGL inhibitor
CN110290791A (en) 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 Pharmaceutical preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAZIL M K ET AL: "HEMODYNAMIC EFFECTS OF AMLODIPINE AND BENAZEPRILAT IN SPONTANEOUSLYHYPERTENSIVE RATS", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, US, vol. 21, no. 3, 1 March 1993 (1993-03-01), pages 405 - 411, XP000579051, ISSN: 0160-2446 *
KUSCHNIR, E. ET AL.: "Treatment of patients with Essential Hypertension: Amlodipine 5mg/Benazepril 20mg Compared with Amlodipine 5mg, Benazepril 20mg, and Placebo", CLINICAL THERAPEUTICS, vol. 18, no. 6, 1996, pages 1213 - 1224, XP001017938 *
MESSERLI, F.H.; OPARIL, S.; FENG, Z.: "Comparison of Efficacy and Side Effects of Combination Therpay of Angiotensin-Converting Enzyme Inhibitor (Benazepril) with Calcium Antagonist (either Nifedipine of Amlodipine) versus High-Dose Calcium Antagonist Monotherapy for Systemic Hypertension", AMERICAN JOURNAL OF CARDIOLOGY, vol. 86, no. 11, 1 December 2000 (2000-12-01), pages 1182-7, XP001017939 *
WEIR, M.R.: "Effects of Low Dose Combination Therapy with Amlodipine / Benazepril on Systolic Blood Pressure", CARDIOVASCULAR REVIEWS AND REPORTS, vol. 20, no. 7, 1999, pages 368 - 374, XP001017941 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043615A3 (en) * 2001-11-23 2004-02-19 Joachim Schrader Hypertonia treatment during the acute phase of a cerebrovascular accident
WO2003043615A2 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
WO2004075856A2 (en) * 2003-02-24 2004-09-10 Novacardia, Inc. Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
WO2004075856A3 (en) * 2003-02-24 2005-03-31 Novacardia Inc Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
JP2006518765A (en) * 2003-02-24 2006-08-17 ノヴァカーディア，インク． Method of treating disease using an adenosine A1 receptor antagonist
US7579331B2 (en) 2003-04-25 2009-08-25 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
WO2005037278A3 (en) * 2003-10-20 2007-05-10 Novartis Ag Tbenazpril and amlodipine for reducing cardiovascular morbidity
WO2005037278A2 (en) * 2003-10-20 2005-04-28 Novartis Ag Tbenazpril and amlodipine for reducing cardiovascular morbidity
AU2004281541B2 (en) * 2003-10-20 2008-05-01 Novartis Ag Tbenazpril and amlodipine for reducing cardiovascular morbidity
WO2005074927A1 (en) * 2004-02-09 2005-08-18 Novartis Ag Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension
WO2005079772A2 (en) * 2004-02-18 2005-09-01 Sepracor Inc. Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
WO2005079772A3 (en) * 2004-02-18 2005-11-03 Sepracor Inc Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
WO2006085208A3 (en) * 2005-02-11 2006-10-19 Ranbaxy Lab Ltd Stable solid dosage forms of amlodipine and benazepril
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
EP1797885A1 (en) * 2005-09-28 2007-06-20 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007040511A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1930008A1 (en) * 2005-09-28 2008-06-11 Teva Pharmaceutical Industries Ltd Sable composition of benazepril hydrochloride
EP1932528A1 (en) * 2005-09-28 2008-06-18 Teva Pharmaceutical Industries Ltd Stable composition of amlodipine besylate
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US10874618B2 (en) 2011-12-21 2020-12-29 Elanco Tiergesundheit Ag Compositions for treatment of heart failure in dogs

Also Published As

Publication number Publication date
IL156136A0 (en) 2003-12-23
WO2002049646A1 (en) 2002-06-27
PL362252A1 (en) 2004-10-18
CZ20031677A3 (en) 2003-10-15
KR20040007420A (en) 2004-01-24
EP1345607A1 (en) 2003-09-24
IL190802A0 (en) 2008-11-03
RU2003121019A (en) 2005-01-20
DE60122928T2 (en) 2007-09-06
SI1345607T1 (en) 2007-02-28
EP1345607B1 (en) 2006-09-06
NO20032766L (en) 2003-08-14
SK7652003A3 (en) 2003-12-02
JP2010043111A (en) 2010-02-25
IL190801A0 (en) 2008-11-03
DK1345607T3 (en) 2006-12-27
EP1674099A1 (en) 2006-06-28
IL156267A0 (en) 2004-01-04
ZA200304514B (en) 2004-05-10
CN1461218A (en) 2003-12-10
JP2004519440A (en) 2004-07-02
ATE338549T1 (en) 2006-09-15
NO20032765D0 (en) 2003-06-17
HUP0302455A3 (en) 2005-05-30
CA2432638A1 (en) 2002-06-27
CA2432282A1 (en) 2002-06-27
HUP0302455A2 (en) 2003-11-28
AU2002232620B9 (en) 2005-11-24
AU2581601A (en) 2002-07-01
CN1481241A (en) 2004-03-10
NO20032766D0 (en) 2003-06-17
AU2001225816B2 (en) 2005-10-13
HUP0302456A3 (en) 2004-05-28
MXPA03005463A (en) 2003-09-25
BR0116228A (en) 2003-12-30
CZ301424B6 (en) 2010-02-24
AU3262002A (en) 2002-07-01
PT1345607E (en) 2007-01-31
CY1106275T1 (en) 2011-10-12
PL360989A1 (en) 2004-09-20
ECSP034658A (en) 2003-07-25
CZ20031678A3 (en) 2003-10-15
NZ526467A (en) 2005-04-29
KR20030061840A (en) 2003-07-22
BR0017386A (en) 2004-01-13
NO20032765L (en) 2003-08-14
JP2004516266A (en) 2004-06-03
HUP0302456A2 (en) 2003-11-28
SK7642003A3 (en) 2003-11-04
EP1365761A1 (en) 2003-12-03
AU2002232620B2 (en) 2005-11-03
DE60122928D1 (en) 2006-10-19
ES2272565T3 (en) 2007-05-01
HK1059566A1 (en) 2004-07-09
MXPA03005462A (en) 2003-09-25
KR20090033914A (en) 2009-04-06
RU2292206C2 (en) 2007-01-27

Similar Documents

Publication Publication Date Title
AU2001225816B2 (en) Therapeutic combination of amlodipine and benazepril
CZ292224B6 (en) Pharmaceutical composition process of its preparation and use
CZ20023381A3 (en) Compound pharmaceutical preparations containing AT1-receptor antagonist and/or HMG-CoA reductase and/or ACE inhibitor
US6162802A (en) Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
WO2009010810A2 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
PL206069B1 (en) Tablet comprising cetirizine and pseudoephedrine
RU2182002C2 (en) Composition containing fixed dose of angiotensin-transforming enzyme and calcium canal antagonist and method for producing the composition and treating cardiovascular diseases
US20040048905A1 (en) Therapeutic combination of amlodipine and benazepril
US20080287412A1 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
ZA200304330B (en) Therapeutic combination of amlodipine and benazepril.
NZ526385A (en) High dose therapeutic combination of amlodipine and benazepril
US4962105A (en) Potentiation of antihypertensive effect of ace inhibitors
WO2011027021A1 (en) A method for the treatment of hypertension
KR102066832B1 (en) Formulation having improved madescent and dissolution rate comprising Telmisartan or its pharmaceutically acceptable salt
KR20180132911A (en) A pharmaceutical composition comprising a beta blocker, a conversion enzyme inhibitor and an antihypertensive agent or an NSAID

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 156136

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001225816

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/04330

Country of ref document: ZA

Ref document number: 200304330

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020037007578

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000989288

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 526385

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002550985

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-1678

Country of ref document: CZ

Ref document number: 2432638

Country of ref document: CA

Ref document number: 947/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 7652003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005462

Country of ref document: MX

Ref document number: 008200807

Country of ref document: CN

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 1200300631

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 10450345

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-1678

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000989288

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037007578

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 526385

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526385

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001225816

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000989288

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2003-1678

Country of ref document: CZ